PROTECTIX 400 MG/2000 MG SPOT-ON SOLUTION FOR DOGS OVER 25 KG UP TO 40 KG

Authorised

- Imidacloprid
- Permethrin

Product identification

Medicine name:
PROTECTIX 400 MG/2000 MG SPOT-ON SOLUTION FOR DOGS OVER 25 KG UP TO 40 KG

Active substance:
Imidacloprid

Permethrin

Target species:
Dog

Route of administration:
Cutaneous use

Product details

Active substance and strength:
Imidacloprid

400.00 milligram(s) / 1.00 Pipette

Permethrin
2000.00 milligram(s) / 1.00 Pipette

Pharmaceutical form:
Spot-on solution

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP53AC54

Legal status of supply:
Veterinary medicinal product not subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Croatia

Package description:
Pack containing 1 PET/PE/aluminium/surlyn sachet containing one white polypropylene unit dose pipette
Pack containing 2 PET/PE/aluminium/surlyn sachets each containing one white polypropylene unit dose pipette
Pack containing 3 PET/PE/aluminium/surlyn sachets each containing one white polypropylene unit dose pipette
Pack containing 4 PET/PE/aluminium/surlyn sachets each containing one white polypropylene unit dose pipette
Pack containing 6 PET/PE/aluminium/surlyn sachets each containing one white polypropylene unit dose pipette
Pack containing 12 PET/PE/aluminium/surlyn sachets each containing one white polypropylene unit dose pipette
Pack containing 24 PET/PE/aluminium/surlyn sachets each containing one white polypropylene unit dose pipette

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:
Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Beaphar B.V.

Marketing authorisation date:
9/06/2025

Manufacturing sites for batch release:
Beaphar B.V.

Responsible authority:
Ministry Of Agriculture Veterinary And Food Safety Directorate

Authorisation number:
UP/I-322-05/25-01/511

Date of authorisation status change:
9/06/2025

Reference member state:
France

Procedure number:
FR/V/0433/004

Concerned member states:
Croatia Cyprus Czechia Germany Greece Hungary Italy Latvia Lithuania Malta Netherlands Poland Portugal Romania Slovakia Slovenia Spain

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents

eu-puar-frv0433004-mr-rpe805-en.pdf